Acute kidney injury following percutaneous edge-to-edge vs. minimally invasive surgical mitral valve repair: incidence, predictors and prognostic value

EuroIntervention. 2018 Feb 20;13(14):1645-1651. doi: 10.4244/EIJ-D-17-00131.

Abstract

Aims: This study sought to determine the incidence and identify predictors of acute kidney injury (AKI) following percutaneous edge-to-edge mitral valve repair (PMVR) and compare the risk of AKI between PMVR and surgical mitral valve repair (SMVR).

Methods and results: We performed a single-centre analysis of 378 patients receiving treatment for mitral regurgitation (196 consecutive patients undergoing PMVR and 182 patients undergoing SMVR). The incidence of AKI (any stage according to KDIGO) following PMVR was 17.9%. Intervention duration (OR 1.01, 95% CI: 1.00-1.02) and peripheral vascular disease (OR 7.69, 95% CI: 3.25-18.17) predicted AKI after PMVR. Patients suffering from AKI after PMVR demonstrated poorer survival (median followup 428 days). SMVR patients were significantly younger, had fewer comorbidities and better renal function at baseline. Nevertheless, AKI occurred numerically more often after SMVR than PMVR (25.8% vs. 17.9%, p=0.060), and a multivariable regression model adjusting for differences between both groups confirmed a significantly lower risk for AKI following PMVR (OR 0.22, 95% CI: 0.11-0.44, p<0.001).

Conclusions: These data show a significant incidence of AKI after PMVR that must be taken into account in periprocedural care. Nevertheless, our data suggest that SMVR carries an even higher risk of AKI, which should be considered when a decision has to be made between the two therapies.

Publication types

  • Comparative Study

MeSH terms

  • Acute Kidney Injury / epidemiology*
  • Acute Kidney Injury / mortality
  • Aged
  • Aged, 80 and over
  • Female
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Minimally Invasive Surgical Procedures / adverse effects*
  • Mitral Valve / surgery*
  • Mitral Valve Insufficiency / surgery
  • Postoperative Complications / epidemiology*
  • Prognosis